Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.

被引：0
|
作者：
Schmidinger, Manuela
Bojic, Marija
Vogl, Ursula Maria
Klingler, Christoph
Kramer, Gero
Zielinski, Christoph
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
[3] Med Univ Vienna, Ctr Canc, Vienna, Austria
[4] Dept Med 1, Div Oncol, Vienna, Austria
[5] Dept Urol, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15090
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Liver-directed therapy (LDT) for metastatic renal cell carcinoma (mRCC): Single center experience.
    Raychaudhuri, Ruben
    Bylow, Kathryn A.
    Lea, William
    Byun, John
    Zellmer, Timothy
    Burfeind, John D.
    Riese, Matthew John
    Kilari, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
    Hwang, Eugene
    Lee, Hyo Jin
    Sul, Chong Koo
    Lim, Jae Sung
    KOREAN JOURNAL OF UROLOGY, 2010, 51 (07) : 450 - 455
  • [33] Targeted treatment beyond third-line in metastatic Renal Cell Carcinoma (mRCC): Single center outcome of 22 patients
    Vallet, S.
    Hoefner, T.
    Pahernik, S.
    Tosev, G.
    Hadaschik, B.
    Duensing, S.
    Hohenfellner, M.
    Jaeger, D.
    Gruellich, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 91 - 91
  • [34] 10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).
    Chow, Shien
    Pillai, Manon Rhys
    Galvis, Victoria
    Leach, Rebecca
    Keene, Elizabeth
    Chan, Kevin
    Spencer-Shaw, Andrea
    Thistlethwaithe, Fiona
    Hawkins, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib - a single center retrospective analysis
    Seidel, C.
    Fenner, M.
    Reuter, C.
    Ivanyi, P.
    Ganser, A.
    Gruenwald, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [36] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience
    Matrana, Marc Ryan
    Shetty, Aditya V.
    Atkinson, Bradley J.
    Xiao, Lianchun
    Corn, Paul G.
    Millikan, Randall E.
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naive metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
    George, Saby
    Herbst, Laurie
    Sikorski, Marcus
    Diraddo, Ann Marie
    Azabdaftari, Gissou
    Roche, Charles
    Kauffman, Eric
    Li, Qiang
    Schwaab, Thomas
    Levine, Ellis Glenn
    Pili, Roberto
    Chatta, Gurkamal S.
    Appleman, Leonard Joseph
    Groman, Adrienne
    Parikh, Rahul Atul
    Hutson, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Cosmai, L.
    Vignani, F.
    Prati, G.
    Scagliarini, S.
    Berselli, A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2017, 28 : 17 - 17
  • [39] Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
    Donskov, F.
    Carus, A.
    Barrios, C. H.
    Escudier, B.
    Li, S.
    Perkins, J.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S136 - S136
  • [40] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Scagliarini, S.
    Vignani, F.
    Prati, G.
    Cosmai, L.
    Berselli, A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2017, 28
12345